drugset / Trial / NCT07301723
A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants
NaSingle-groupOpen-labelOther
Summary
The goal of this clinical trial is to learn about the absolute bioavailability of cenerimod in healthy participants. It will also provide information about the safety of cenerimod. Participants will receive one tablet with cenerimod, followed by an intravenous (i.v.) infusion with a 14C-radiolabeled cenerimod microtracer (cenerimod with a very low dose of radioactivity) 6 hours later. Participants will stay at the clinic for a total of 4 days, and will return to the clinic for further tests over the course of approximately 3 months.
Timeline
- Start
- 2025-12-11
- Primary completion
- 2026-03-18
- Completion
- 2026-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenerimod | Small molecule | 7.5 ug | Oral |
| Subject | Cenerimod | Small molecule | 4 mg | Oral |
Indications
No indication recorded.